Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Quietly Acquires microRNA Company Actigenics ...

NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
 
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
 
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancer-specific markers, infection-specific markers, inflammation-specific
markers, and surrogate markers of complex regulatory mechanisms,” the company said.
 
Cepheid may also develop diagnostic tests associated with the therapeutic applications.
 
Financial details were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.